Further Novartis H1N1 vaccine cleared in Switzerland

* Celtura third Swine flu vaccine approved in Switzerland

* Cleared for use in adults, children from 3 years

* Those over 40 need two doses

ZURICH, Nov 13 (Reuters) - Switzerland has approved Swiss drugmaker Novartis AG's (NOVN.VX) Celtura H1N1 swine flu vaccine as it rolls out its national vaccination programme ahead of the winter flu season, regulators said on Friday.

Swissmedic said it was adding Celtura to the list of approved H1N1 vaccines after giving the green light to GlaxoSmithKline's (GSK.L) Pandemrix and Novartis's Focetria at the end of October. [ID:nLU162500] Celtura was cleared for use in children over three years' old and adults of all ages, although those over 40 years would need two doses, three weeks apart to achieve the necessary level of immunisation, Swissmedic said.

Switzerland has ordered 13 million doses of vaccine from Novartis and Glaxo for its programme to fend off the virus, which could eventually affect 2 billion people globally, according to the World Health Organisation.

Swiss drugmaker Novartis, which has already started to ship doses of its vaccines Fluvirin to the United States and Focetria to other countries around the world, said last week that Germany had already approved Celtura. Novartis has said it expects a fourth-quarter sales boost of up to $700 million from its H1N1 pandemic vaccine.

It has submitted a registration for Celtura in Japan and will seek further approvals in a number of other countries, Novartis said.

(Reporting by Jason Rhodes; editing by Simon Jessop)